BioSpace News Archive

BioInvent International AB announces that it receives a milestone payment following clinical progression of an out-licensed antibody.

Momentum in several areas, not least the development of our cutting-edge project fostroxacitabine bralpamide.

Active Biotech’s Annual Report 2021 is now available for download at www.activebiotech.com.

Royal Philips announced the intention to issue one or more series of notes under its European Medium Term Note program, as well as a series of liability management transactions, which are expected to extend the company’s debt maturity profile.

WuXi Advanced Therapies, a wholly owned subsidiary of WuXi AppTec, and A*STAR’s Bioprocessing Technology Institute, announced a new partnership to bring WuXi ATU’s proprietary Tetracycline-Enabled Self-Silencing Adenovirus technology to the Asia-Pacific region.

An age-based dementia grading and predicting model by Taiwanese company AcroViz Inc. has demonstrated in a study its potential as an imaging biomarker used for grading dementia severity and predicting the change in this severity over the ensuing years.

Acclaro Corporation, breaks new ground in medical devices for aesthetics with their revolutionary UltraClear™ system.

Centogene N.V. announced it has extended its partnership with Takeda to diagnose patients with rare metabolic and rare neurodegenerative diseases.

Pulse Biosciences, Inc. announced today it will report financial results for the first quarter of 2022 after market close on Wednesday, May 11, 2022. Company management will host a corresponding conference call beginning at 1:30pm PT.

Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that seven abstracts from the company’s pipeline, including late-breaking data from the ATHENA-MONO Phase 3 clinical trial evaluating Rubraca monotherapy versus placebo and imaging of solid tumors using FAP-2286, will be presented in oral and poster sessions during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.